Matzinger Oscar Date of birth

Curriculum Vitae
1. General information
Name:
Matzinger Oscar
Date of birth: 07.12.1970
Nationality/Origin:
Swiss/Zurich
Family status:
Married to Carole Matzinger-Besson
Children: Inès, 19.08.08 Robin, 27.01.2011
Private address:
Professional address:
Rue du Midi 19, 1800 Vevey, Switzerland
+41 79 541.75.10 Oscar.Matzinger@gmail.com
Service de radio-oncologie, CHUV 1011 Lausanne, Switzerland
+41 79 556.48.21 Oscar.Matzinger@chuv.ch
Language: Bilingual: French & (Swiss-) German
Spoken & Written: English
2. Academic titles
• Thesis in medicine (2002), University of Lausanne, Prof. Luc Tappy
“Effects of fatty acids on exercise plus insulin-induced glucose utilization in trained and sedentary subjects”
• Board Certified (FMH) in radiation-oncology (2007)
• Privat-Docent & Senior lecturer (“Privat Docent & Maître d’enseignement et de recherche”) (2011), University of
Lausanne.
3. Pre-graduate
• Medical school at University of Lausanne (1992 – 1998)
• Graduation 1998
4. Post-graduate
a. Before Board Certification
4.1999 – 9.2000 Resident, institute of physiology, University of Lausanne
Prof Eric Jécquier & Luc Tappy
10.2000 – 3.2001 Resident, department of internal medicine, CHUV - Lausanne
Prof Pascal Nicod & Gérard Weber.
4.2001 – 9.2001 Resident, department of medical oncology, CHUV
Prof Serge Leyvraz
10.2001 – 9.2002 Resident, department of radiology, CHUV
Prof Pierre Schnyder
10.2002 – 3.2005 Resident, department of radiation oncology, CHUV
Prof René-Olivier Mirimanoff
4.2005 – 3.2006 Resident, department of radiation oncology, Inselspital - Bern
Prof Richard Greiner
4.2006 –12.2006 Deputy-Chief Resident (chef de clinique adjoint), department of radiation oncology, Inselspital
Prof Richard Greiner & Daniel Aebersold
b. After Board Certification
1.2007 – 3.2008 Chief Resident (“chef de Clinique”), in charge of H&N and lung cancer, melanoma and
sarcoma, department of radiation oncology, CHUV, Prof René-Olivier Mirimanoff
4.2008 – 3.2009 Radiotherapy Quality Assurance Fellow & Clinical research physician (CRP), European
Organisation of Research in Treatment of Cancer (EORTC), Brussels
4.2009 – 12.2009 Chief Resident, in charge of GI and lung cancer, melanoma, and sarcoma, department of
radiation oncology, CHUV, Prof René-Olivier Mirimanoff
1.2010 – 3.2011 Associate physician (“médecin associé”), in charge of GI and lung cancer, melanoma, and
sarcoma, department of radiation oncology, CHUV, Prof René-Olivier Mirimanoff
4.2011 – actual Senior physician (“médecin adjoint”), in charge of GI and lung cancer, melanoma, and sarcoma,
department of radiation oncology, CHUV, Prof René-Olivier Mirimanoff & Prof Jean Bourhis
6.2012 – 10.2012 Acting head of radiation-oncology department, CHUV
As of 2013
As of 2016
Designated Head of department, Radiation Oncology department, Hospital of Riviera, Vevey
Designated Head of department, department of medical oncology and radiation oncology,
Hospital of Rennaz

2
5. Teaching
2004 – actual Bedside teaching, university of Lausanne
2005 – 2006 Participation in pre- and post-graduate teaching, department of radiation oncology, Inselspital
2004 – actual Participation in pre-graduate teaching, radiation oncology department CHUV
2004 – actual Participation post-graduate teaching, oncology & radiation-oncology department, CHUV
2010 – actual In charge of the oncology teaching to the radiology and radiation oncology technologist school
of Lausanne (“école HES Lausanne”)
2010 – actual In charge of the « Journal Club » radiation oncology department, CHUV
2010 – actual Formal teaching to medical students, University of Lausanne:
• Module B3.2: Introduction to thoracic cancer
• Module M1.3: Radiotherapy for lung cancer
• Module M 2.5: Multidisciplinary lesson on colo-rectal cancer
2011 – actual PD lessons: Radiation oncology treatment in thoracic and digestive cancer
6. Management
Former officer (premier-lieutenant), Swiss army (artillery)
2004 – 2007 Vice president and COO, Swiss association of medical residents (ASMAC; 20 ≈ employees)
2010 Management course for management position of the CHUV
2010 – actual Complete reorganisation of the workflow, radiation oncology department, CHUV
2010 – actual Creation of the business plan & medical project leader of the future department of radiation
oncology, hospital of Riviera, Vevey
2010 – actual Medical project leader of the future medical and radiation oncology department of the future
hospital of Rennaz
8.2011 – 3.2012 Academic supervisor of the radiation oncology department of Sion (clinical supervision;
workflow analysis & improvement; equipment adequacy analysis)
7. Award
03.2010 Label FBM (faculty of biology and medicine, Lausanne) 2010 award:
« Investigator-in-training award in clinical sciences ».
8. Medical & scientific board activity
2000 – 2004 Member of the board of the Swiss association of medical interns (ASMAC/VSAO)
2002 – 2004 President of ASMAV (ASMAC, section Vaud)
2000 – 2007 Delegate at the medical chamber of FMH
2004 – 2007 Vice-president ASMAC/VSAO
2007 – actual Executive board member SASRO (Scientific Association of Swiss Radiation Oncology), in
charge of communication
2008 – actual Executive board member SWITRO SWITRO (Swiss trials in Radiation Oncology), in charge of
implementation of QA programs in Swiss trials (SAKK & SASRO)
2010 – actual Executive board member & secretary of SRO (Swiss society of radiation oncology)
2010 – actual Board member for federal examination in radiation oncology
2011 – actual Expert for federal examination in radiation oncology
2008 – actual Chairman Gastro-intestinal working party EORTC Radiation Oncology Group
2008 – actual Steering committee member of the « EORTC - Radio Oncology Group (ROG) »
2008 – actual Executive board member of the « EORTC (ROG) Quality Assurance group »
2010 – actual Executive board member ARRAD (Association Romande de Radioprotection)
2011 – actual Representative of the CHUV in the « Swiss Proton Task Force ».
2009 – actual Reviewer in: « Lancet Oncology »; « International Journal of Radiation Oncology Biology and
Physics » « Radiotherapy & Oncology »; « Lung Cancer »; « Case reports in medicine »;
« Melanoma research »; « Rare Tumors »; « World Journal of Surgical Oncology »
2011 – actual Clinical protocol peer-reviewer for: « Institut National du Cancer – INCa (France) »; « Nova
Scotia Health Research Foundation »
9. Membership scientific societies
2008 – actual EORTC groups: RT & Lung & GI & H&N
2008 – actual SAKK groups: RT & Lung & GI
2003 – actual ESTRO (European Society for Therapeutic Radiology and Oncology)
2010 – actual ASTRO (American Society for Therapeutic Radiology and Oncology)

3
10. Research activity
GCP Certification, level 3 (Swiss medic recognition: 27.10.2011)
a) Clinical research:
Strong clinical research activity in the frame of EORTC; SAKK and local protocols.
Main focus:
• GI cancer (anal cancer; gastric cancer)
• Lung cancer
• Quality assurance in clinical trials
Principal investigator:
- PARADAC: pooled analysis of all phase II & III randomised trials in anal cancer (EORTC, UKCCR,
RTOG, SWOG, FNLCC). Publication Q1 2013
- Phase II multicentric trial (Lausanne, Geneva, Sion): “Concomitant intensity-modulated radiotherapy
combined to capecitabine, mitomycin, and panitumumab in patients with stage II-IIIB squamous-cell
carcinoma of the anal canal”. Approval of ethic committee and Swiss Medic. Start Q4 2012
Co – Principal investigator:
- Co-author of a multicentric phase IB trial in gastric cancer (Lausanne; St-Gall): “Traitement de
cetuximab en combinaison avec une radiothérapie locale et une chimiothérapie périopératoire dans le
cancer gastrique localement avancé et résécable”. Study started Q3 2012
- Author of the radiotherapy chapter and responsible for the radiotherapy QA of SAKK 16-08 study
in lung cancer (Preoperative chemotherapy and radiotherapy with concomitant Cetuximab in non-small
cell lung cancer (NSCLC) patients with IIIB disease. A multicentre phase II trial).
- Member of the writing committee: EORTC trial 22043-30041: Study co-ordinator Prof. Michel Bolla.
“Postoperative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus
post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0 / pT2R1N0, Gleason
score 5-10 prostatic carcinoma. A phase III study”.
Local PI & European expert for the radiation oncology quality:
- EORTC 40084-22084 - RTOG 0848: « A Phase III Trial Evaluating Both Erlotinib and Chemoradiation
as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma ».
3 US and 3 EU experts review all radiotherapy plans before treatment authorisation
Local-PI:
- Etude EORTC 62092-22092: « A phase III randomized study of preoperative radiotherapy plus surgery
versus surgery alone for patients with Retroperitoneal sarcoma (STRASS) ».
b) Radiobiology:
In charge of the radiobiology lab of CHUV since 2011. Ongoing projects:
• Radio-sensitization effect of TAT-RasGAP 317-326 peptide with Prof Widmann, Institute of
physiology, University of Lausanne
• Radio-sensitization effect of PP242 with Dr Olivier Dormond, Abdominal surgery department,
CHUV
• Radio-sensitization effect of Debio-1143 in vitro and in vivo (confidential). Debiopharm, Lausanne
c) Founding:
Onco Suisse: main co-investigator; 350.000 CHF « Characterization of T cell activation and
suppression in melanoma patients by ex vivo analysis of myeloid, lymphoid and tumor cells »
EORTC: 200'000 €; IMAGE trial: « EORTC Strategy Meeting 2008»
Amgen: 500’000 CHF; “Concomitant intensity-modulated radiotherapy combined to capecitabine,
mitomycin, and panitumumab in patients with stage II-IIIB squamous-cell carcinoma of the anal canal”

4
Debiopharm: 167'000 CHF; « Radiosensitizing effect of Debio-1143 in vitro and in vivo ».
Merck Serono: main co-investigator; 147’000 CHF: “Integration of cetuximab, in combination with
local radiotherapy, in perioperative chemotherapy of resectable and locally advanced gastric cancer: A
pilot phase II-trial”.
d) Patent:
Pending; co-inventor (C. Widmann & O. Matzinger): « use of a peptide enhancing the ability of radiation
therapy to kill cancer cells » (confidential).
11. Publications
Number of original peer-reviewed papers: 31
1. Joosten A, Matzinger O, Jeanneret-Sozzi W, Bochud F, Moeckli R. Evaluation of organ-specific peripheral
doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation therapy for breast cancer
based on Monte Carlo and convolution/superposition algorithms: Implications for secondary cancer risk
assessment. Radiother Oncol. 2013 Jan 22.
2. Tsoutsou PG, Sozzi WJ, Matzinger O, Ozsahin M. Nomograms Predicting Locoregional Recurrence in the
Subtype Era of Breast Cancer. J Clin Oncol. 2012 Dec 26.
3. Perentes J, Bopp S, Krueger T, Gonzalez M, Jayet PY, Lovis A, Matzinger O, Ruffieux C, Ris HB, Letovanec
I, Peters S. Ann Thorac Surg. Impact of lung function changes after induction radiochemotherapy on resected
T4 non-small cell lung cancer outcome. 2012 Dec;94(6):1815-22.
4. Fairchild A, Aird E, Fenton PA, Gregoire V, Gulyban A, Lacombe D, Matzinger O, Poortmans P, Ruyskart P,
Weber DC, Hurkmans CW. EORTC Radiation Oncology Group quality assurance platform: establishment of
a digital central review facility. Radiother Oncol. 2012 Jun;103(3):279-86
5. Rossier C, Dunet V, Matzinger O, Prior JO. PET/CT and radiotherapy: indications and potential applications.
Cancer Radiother. 2012 Apr;16(2):152-63
6. Ozsahin M, Santa Cruz O, Bouchaab H, Matzinger O, Tsoutsou PG. Definitive organ-sparing treatment of
anal canal cancer: can we afford to question it J Clin Oncol. 2012 Feb 20;30(6):673-4; 674-5
7. Tsoutsou PG, Sozzi WJ, Matzinger O, Ozsahin M. Personalizing Locoregional Treatment in the Adjuvant
Setting of Early Breast Cancer on the Basis of Molecular Background: An Exciting Enigma. J Clin Oncol.
2011 Dec 10;29(35):4721-4722
8. Khanfir K, Elhfidh M, Anchisi S, Matzinger O, Bieri S, Mirimanoff RO, Ozsahin M, Zouhair A. Sequential or
concomitant chemotherapy in limited stage small-cell lung cancer. Swiss Med Wkly. 2011 May 31
9. Gonzalez M, Krueger T, Perentes JY, Matzinger O, Peters S, Ris HB. Extrapleural pneumonectomy with
venous confluence resection for stage IVA thymic tumors. Ann Thorac Surg 2011;91:941-943
10. Zouhair A, Matzinger O, Azria D, Gaye MP, Ugurluer G, El Hfid M, Mirimanoff RO, Ozsahin M. Postoperative
radiochemotherapy of the head and neck: Towards new standards Cancer Radiother 2010;14:217-
221
11. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH,
Cengiz M, Krengli M, Matzinger O, Zouhair A. Outcome and prognostic factors in olfactory neuroblastoma: a
rare cancer network study. Int J Radiat Oncol Biol Phys 2010;78:992-997
12. Matzinger O, Heimsoth I, Poortmans P, Collette L, Struikmans H, Van Den Bogaert W, Fourquet A, Bartelink
H, Ataman F, Gulyban A, Pierart M, Van Tienhoven Toxicity at three years with and without irradiation of the
internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial
22922/10925). Acta Oncol 2010;49:24-34
13. Pehlivan B, Zouhair A, Luthi F, Bron L, Pasche P, Dragusanu D, Azria D, Matzinger O, Mirimanoff RO,
Ozsahin M. Decrease in hemoglobin levels following surgery influences the outcome in head and neck cancer
patients treated with accelerated postoperative radiotherapy. Ann Surg Oncol 2009;16:1331-1336
14. Pehlivan B, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W,
Mirimanoff RO, Zouhair A, Ozsahin M.. Feasibility and efficacy of accelerated weekly concomitant boost
postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced
head and neck cancer. Ann Surg Oncol 2009;16:1337-1343
15. Matzinger O, Zouhair A, Mirimanoff RO, Ozsahin M. Radiochemotherapy in locally advanced squamous cell

5
carcinomas of the head and neck. Clin Oncol (R Coll Radiol) 2009;21:525-531
16. Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K,
Radosevic-Jelic L, Mueller RP, Maingon P, Collette L, Bosset JF. Mitomycin C with continuous fluorouracil
or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation
for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009;45:2782-2791
17. Matzinger O, Poortmans P, Giraud JY, Maingon P, Budiharto T, van den Bergh AC, Davis JB, Musat E,
Ataman F, Huyskens DP, Gulyban A, Bolla M. Quality assurance in the 22991 EORTC ROG trial in localized
prostate cancer: dummy run and individual case review. Radiother Oncol 2009;90:285-290
18. Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P,
Collette L, Kuten A. EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for
neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol
2009;92:164-175
19. Matzinger O, Duclos F, van den Bergh A, Carrie C, Villa S, Kitsios P, Poortmans P, Sundar S, van der Steen-
Banasik EM, Gulyban A, Collette L, Bolla M. Acute toxicity of curative radiotherapy for intermediate- and
high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer 2009;45:2825-2834
20. Ghadjar P, Matzinger O, Isaak B, Behrensmeier F, Stroux A, Rentsch CA, Thalmann GN, Aebersold DM.
Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensitymodulated
radiation therapy in intermediate- and high-risk prostate cancer. Radiother Oncol 2009;91:237-242
21. Ozsahin M, Matzinger O, Zimmermann M, Zouhair A. Radio-chemotherapy in head and neck cancer
(EGFR+). Bull Cancer 2007;94:828-832
22. Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A. Feasibility
and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative
accelerated concomitant-boost radiation therapy. Arch Otolaryngol Head Neck Surg 2006;132:141-145
23. Coucke PA, Notter M, Stamm B, Matter M, Fasolini F, Schlumpf R, Matzinger O, Bouzourene H.
Preoperative hyper-fractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC)
immediately followed by surgery. A prospective phase II trial. Radiother Oncol 2006;79:52-58
24. Delaloye J, Merlani G, Petignat C, Wenger A, Zaman K, Monnerat C, Matzinger O, Beck Popovic M,
Vuichard P, Ketterer N, Tarr PE. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy:
reactivation of asymptomatic colonization Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):751-8. PubMed
PMID: 15605182
25. Michielin O, Udry E, Periard D, Matzinger O, Lobrinus JA, Stupp R. Irinotecan-induced interstitial
pneumonia. Lancet Oncol. 2004 May;5(5):322-4. PubMed PMID: 15120670
26. Zouhair A, Azria D, Coucke P, Matzinger O, Bron L, Moeckli R, Do HP, Mirimanoff RO, Ozsahin M.
Decreased local control following radiation therapy alone in early-stage glottic carcinoma with anterior
commissure extension. Strahlenther Onkol. 2004 Feb;180(2):84-90
27. Couke PA, Jichliski P, Matzinger O, Ozsahin M, Bulling SM, Zouhair A. Antiandrogen gynecomastia: an
inescapable harm Radiotherapy: a simple and efficient solution! Rev Med Suisse Romande. 2004
Jan;124(1):51-4
28. Henchoz E, D'Alessio DA, Gillet M, Halkic N, Matzinger O, Goy JJ, Chioléro R, Tappy L, Schneiter P.
Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients.
Transplantation. 2003 Sep 27;76(6):923-9
29. Delarue J, Matzinger O, Binnert C, Schneiter P, Chioléro R, Tappy L. Fish oil prevents the adrenal activation
elicited by mental stress in healthy men. Diabetes Metab. 2003 Jun;29(3):289-95
30. Matzinger O, Schneiter P, Tappy L. Effects of fatty acids on exercise plus insulin-induced glucose utilization
in trained and sedentary subjects. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E125-31
31. Rigalleau V, Binnert C, Minehira K, Stefanoni N, Schneiter P, Henchoz E, Matzinger O, Cayeux C, Jéquier E,
Tappy L. In normal men, free fatty acids reduce peripheral but not splanchnic glucose uptake. Diabetes. 2001
Apr;50(4):727-32
Book chapter:
Matzinger O. “Esthesioneuroblastoma” in: Management of Rare Adult Tumours, coordinated by Y. Belkacémi, M.
Ozsahin, and R.O. Mirimanoff”. Ed. Springer 2010

6
Invited presentations (only international conferences):
ESTRO 2013 (European society for radiation oncology): « Spincter preservation in anal cancer »
EBCC 2012 (European Breast Cancer Conference) 2012. « Role of radiotherapy in advanced breast cancer »
SAMO 2012 (Swiss Academy of Multidisciplinary Oncology): « Modern technique of radiotherapy in resectable
NSCLC, an alternative approach to surgery »
ECCO 2011 (European Multidisciplinary Cancer Congresses): « Clinical Trial design in surgical and radiation
oncology »
ICTR 2009 (International Conference on Translational Research and Pre-Clinical Strategies in Radiation
Oncology): « The Value of PET in Gastro-esophageal Cancer »
EGAM (EORTC group annual meeting) 2009: « Toxicity of Internal mammary and medial supraclavicular lymph
node chain irradiation in stage breast cancer »
EGAM 2009: « Acute toxicity of curative radiotherapy for localized prostate cancer »
Other oral presentations
ICHNO 2013: D. Viertl, F. Perillo-Adamer, S. Rigotti, H. Maby El Hajjami, A. Vaslin, G. Vuagniaux, C Zanna, O.
Matzinger. Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemioradiotherapy
in LA-SCCHN.
ASTRO 2012 (American society for radiation oncology): D. Viertl, A. Annibaldi, F. Buchegger, M. Özsahin, R-O
Mirimanoff, Ch. Widmann, O. Matzinger
“Tumor Radiosensitization Induced by a-RasGAP Derived Peptide and its Pharmacokinetic in Mice”
4th Symposium on Novel Targeting Drugs and Radiotherapy 2012, Toulouse, France: D. Viertl, A. Annibaldi, F.
Buchegger, M. Özsahin, R-O Mirimanoff, Ch. Widmann, O. Matzinger. “TAT-RasGAP317-326 abolishes in vivo
radio-resistance of p53 defective tumor “
ESTRO 2012: Viertl D, Annibaldi A, Widmann C, Matzinger O. “Radiosensitizing effect of a RasGAP derived
peptide on cell survival in human cancer cells in vitro and in vivo”
SASRO 2012 (Scientific Association of Swiss Radiation Oncology): David Viertl, Allessandro Annibaldi, Mahmut
Özsahin, René-Olivier Mirimanoff, Christian Widmann, Oscar Matzinger. « In vitro and in vivo tumor
radiosensitization induced by TAT-RasGAP317-326 peptide »
ICTR 2012 (International Conference on Translational Research in Radiation Oncology) : Viertl D, Annibaldi A,
Widmann C, Matzinger O. « A TAT-RasGAP derived peptide efficiently sensitizes cancer cells to radiotherapy, an
in vitro and in vivo study »
ESTRO 2011: Matzinger O. « EORTC Radiotherapy Quality Assurance Platform: Establishment of an Integrated
Central Review Facility »
ECCO/ESMO, 2009: Matzinger O « Acute toxicity of curative radiotherapy for intermediate and high risk
localized prostate cancer in the EORTC trial 2299 »
SASRO (Scientific association of Swiss Radiation Oncology), 2007: Matzinger O « Limited Stage Small Cell Lung
Cancer: Results of Combined Modality Treatment »
Abstracts in conferences:
SASRO 2012: H. Bouchaab, S. Peters, H. B. Ris, P. Tsoutsou, M. Pachoud, R. O. Mirimanoff, M.
Ozsahin, O. Matzinger : « Accelerated hypofractionated radiotherapy in inoperable lung cancer using
Tomotherapy: The Lausanne experience »
SASRO 2012: D. Viertl, A. Annibaldi, M. Özsahin, R.-O. Mirimanoff, C. Widmann, O. Matzinger :
« In vitro and in vito tumor radiosensitization induced by TAT-RasGAP317-326 peptide »
ASTRO 2011: Viertl D, Wiedmann ,Annibaldi A, Matzinger O : « A Cell Permeable Rasgap-derived Peptide
Sensitizes Cancer Cells To Radiotherapy »
ASTRO 2011: Matzinger O, Bouchaab H, Ozsahin M, Mirimanoff O. « Helical tomotherapy in the treatement of
anal canal caner »

7
ISREC Symposium 2011: Viertl D, Annibaldi A, Mirimanoff R.-O, Widmann C, Matzinger O : « A Cell
Permeable RasGAP-derived Peptide Sensitizes Cancer Cells to Radiotherapy »
SASRO 2011: Cosinschi A, Khanfir K, Boujelbene N, Herrera F, Pachoud M, Matzinger O : Ozsahin M. « Carotid
sparing in T1-T2 N0 glottic cancer using helical tomotherapy »
ESTRO 2009: Ugurluer G, Ballerini G, Letenneur G, Lacombe C, Pissaturo O, Matzinger O : Montemurro M,
Zouhair A, Mirimanoff RO, Ozsahin M. « Helical tomotherapy (HT) for the treatment of anal canal cancer:
Preliminary clinical results, and dosimetric comparison between HT and intensity-modulated or 3D conformal
radiotherapy »
SASRO 2008: Matzinger O, Ozsahin M, Luthi F: « Induction Chemotherapy followed by concomitant
chemotherapy and IMRT for nasopharyngeal carcinoma »
ASCO 2008: Ozsahin M, Pachoud M, Moeckli R, Letenneur G, Lacombe C, Montemurro M, Betz M, Matzinger
O, Mirimanoff RO, Zouhair A : « Helical tomotherapy in the treatment of anal cancer: Preliminary results »
ASTRO 2007: Matzinger O, Ozsahin M, Khanfir K, ElHfid M, Peters S, Pachoud M, Bieri S, Mirimanoff R.O.
and Zouhair A: « Sequential or Concomitant Chemotherapy and 3D Conformal Radiation Therapy with Dose-
Volume Histogram Assessment in Limited Disease Small Cell Lung Cancer »
ASTRO 2007: Pehlivan B, Zouhair A, Matzinger O, Luthi F, Bron L, Pasche P, Seelentag W, Bulling S,
Mirimanoff R.O. and Ozsahin M: « Accelerated Weekly Concomitant Boost Postoperative Radiation Therapy
Combined to Concomitant Chemotherapy in Patients With Locally Advanced Head and Neck Cancer »
ECCO 2007: Zouhair A, Dragusanu D, Matzinger O, Pehlivan B, Khanfir K, Ris H.B, Stupp R, Moeckli R,
Mirimanoff R.O. and Ozsahin M: « Postoperative 3D Conformal Radiation Therapy With Dose-Volume Histogram
Assessment in Non Small-Cell Lung Cancer »
ECCO 2007: Ozsahin M, Pehlivan B, Matzinger O, Luthi F, Bron L, Pasche P, Seelentag W, Bulling S, Mirimanoff
R.O. and Zouhair A: « Accelerated weekly concomitant boost postoperative radiation therapy combined to
concomitantchemotherapy in patients with locally advanced head and neck cancer »
ASTRO/ASCO/AHNS (Multidisciplinary Head and Neck Cancer Symposium) 2007: Matzinger O, Ozsahin M,
Bron L, Luthi F : « Pilot study of induction chemotherapy followed by concomittant chemotherapy and intensitymodulated
radiotherapy or tomotherapy for nasopharyngeal carcinoma »
ASTRO 2004: Matzinger O, Mirimanoff R.O., Zouhair A. and Ozsahin M: « Decrease in the Hemoglobin Level
Influences the Outcome in Head and Neck Cancer Patients Treated with Postoperative Accelerated Radiation
Therapy »
SASRO 2004: Ozsahin M, Betz M, Matzinger O, Azria D, Stupp R, Luthi F, Pasche P, Mirimanoff RO, Zouhair
A: « Feasibility and efficacy of subcutaneous amifostine in head and neck cancer treated with curative radiation
therapy »
ICHNC 2004 (International Conference on Head and Neck Cancer) Ozsahin M, Betz M, Matzinger O, Azria D,
Luthi F, Pasche P, Mirimanoff RO, Zouhair A. « Feasibility and efficacy of subcutaneous amifostine in head and
neck cancer patients treated with curative radiation therapy »
ASTRO 2004: Ozsahin M, Pasche P, Luthi F, Azria D, Betz M, Matzinger O, Mirimanoff RO, Zouhair A:
« Decreasing hemoglobin level during surgery influences the outcome in head and neck cancer patients treated with
postoperative accelerated radiotherapy »